Connect with us ! Google+ LinkedIn Pinterest YouTube

Collaborations in Research: Management Strategies for Nosocomial infections

Share on Facebook0Tweet about this on TwitterShare on LinkedIn0Share on Google+0Pin on Pinterest0Email this to someone

Queens University, Kingston, Ontario, Canada

Nosocomial infections (NIs) remain an important cause of morbidity, mortality, and increased health care costs in hospitalized patients. This is particularly problematic in intensive care units (ICUs) where NIs occur in 25 to 35 % of ICU patients and account for approximately 25 % of all nosocomial infections in the hospital. In ICU patients, mechanical ventilation is an important risk factor for NIs. Further, since NIs are increasingly caused by multidrug-resistant bacteria, clinicians frequently prescribe broad spectrum antibiotic regimens. In turn, this sets the stage for pseudomembranous colitis (PMC), another potentially lethal NI. The prevention of NIs has the potential to improve patient outcomes and reduce the cost burden of increasingly broad spectrum, prolonged courses of antibiotics administered for suspected or confirmed infections.

Lactoferrin (LF), an 80-kDa, multifunctional glycoprotein of the transferrin family, is distributed widely in humans particularly in secretions of exocrine glands and specific neutrophil granules. The highest concentrations of LF are found in breast milk and colostrum. As an important component of the human innate immune system, it has many appealing properties that may prove effective for the prevention of NIs.

LF has the ability to bind iron, an important element for microbial growth, thereby reducing its availability to microorganisms and making it bacteriostatic. In addition, LF has bactericidal effects on microorganisms attributable to its highly cationic charged terminus, which binds to bacterial surfaces. The binding of LF to the bacterial surface destabilizes the bacterial outer membrane, thus enhancing bacterial susceptibility to osmotic shock, lysozyme, or other antimicrobial molecules. This antibacterial activity has been documented against many important human pathogens, including: Escherichia coliStaphylococcus aureusKlebsiella sp.,Acinetobacter sp., Pseudomonas sp., Salmonella sp., and Proteus sp. Additionally, LF has been shown to exhibit activity against Candida albicans and Candida krusei and to inhibit the formation of biofilms by Pseudomonas aeruginosa and oral bacteria.

Professor John Muscedere and his team are looking at  at lactoferrin in the prevention of nosocomial infections in the critically ill. AOR provided the clinical trial material for this randomized double blind clinical study.

 

References:

  1. Muscedere J, Maslove D, et-al Prevention ofnosocomial infections in critically ill patients with lactoferrin (PREVAIL study): study protocol for a randomized controlled trial. Trials. 2016 Sep 29; 17(1):474.
  1. Cipolla D, Giuffrè M, Mammina C, Corsello G. Prevention of nosocomial infections and surveillance of emerging resistances in NICU. J Matern Fetal Neonatal Med. 2011 Oct; 24 Suppl. 1:23-6
  2. Kaufman DA. Lactoferrin supplementation to prevent nosocomial infections in preterm infants. JAMA. 2009 Oct 7; 302(13):1467-8.

Leave a Reply

Your email address will not be published. Required fields are marked *

Retype the CAPTCHA code from the image
Change the CAPTCHA codeSpeak the CAPTCHA code
 

Protected with IP Blacklist CloudIP Blacklist Cloud

JOIN US NOW
Purus sed vel ultricies, lorem rhoncus. Augue hac, adipiscing risus, sed ac? Pid nunc dignissim, non, ac parturient sociis enim.
Your Information will never be shared with any third party.
SUBSCRIBE TO NEWSLETTER
All rights reserved © Company Name, 2014
Dolor aliquet augue augue sit magnis, magna aenean aenean et! Et tempor, facilisis cursus turpis tempor odio, cursus montes ac turpis. Ultrices! Massa integer augue ridiculus adipiscing, massa cras pid. Turpis placerat scelerisque, vut odio mus non, mattis porttitor, nunc odio, turpis tortor sit? Pid amet, sed facilisis.
  • Goblinus globalus fantumo tandempo
  • Scelerisque cursus dignissim donus
  • Montes vutario lacus quis arcupolisio
  • Leftomato denitro oculus tepircos den
  • Spiratio dodenus christmas popupius
  • Afrenius globalus spiritum tandempo
  • Fitatos vutario lacus quis arcup delis
Here's $3 Off
Apply $3 off at checkout to any AOR product purchase. Just send your name and email and we'll email you your coupon.
Your Information will never be shared with any third party.
JOIN US NOW
Stay ahead of the curve with the latest AOR news, industry trends, and new product launches.
Your Information will never be shared with any third party.
Do you want massive traffic?
Dignissim enim porta aliquam nisi pellentesque. Pulvinar rhoncus magnis turpis sit odio pid pulvinar mattis integer aliquam!
  • Goblinus globalus fantumo tubus dia montes
  • Scelerisque cursus dignissim lopatico vutario
  • Montes vutario lacus quis preambul den lacus
  • Leftomato denitro oculus softam lorum quis
  • Spiratio dodenus christmas gulleria tix digit
  • Dualo fitemus lacus quis preambul pat turtulis
* we never share your e-mail with third parties.
JOIN US TODAY
For the latest:
AOR is committed to your privacy, your information will not be shared with any third party. You may unsubscribe at any time.
COMPANY UPDATES
INDUSTRY TRENDS
PRODUCT LAUNCHES
Nutrition Education
AOR is committed to your privacy, your information will not be shared with any third party. You may unsubscribe at any time.
Science-based facts from our team of top medical experts delivered right to your inbox!
Health Basics
Fitness Advice
JOIGNEZ-NOUS AUJOURD'HUI
Les dernières nouvelles:
AOR s’engage à protéger la confidentialité de vos données. Elles ne seront pas partagées avec des tiers. Vous pouvez vous désabonner à tout moment
MISE À JOUR
TENDANCES DE L'INDUSTRIE
LANCEMENTS DE PRODUITS
JOIN US TODAY
For the latest:
AOR is committed to your privacy, your information will not be shared with any third party. You may unsubscribe at any time.
SPECIAL RETAILER OFFERS
JOIN US TODAY
For the latest:
AOR is committed to your privacy, your information will not be shared with any third party. You may unsubscribe at any time.
MONTHLY PRICE LIST
JOIN US TODAY
For the latest:
AOR is committed to your privacy, your information will not be shared with any third party. You may unsubscribe at any time.
PRODUCT LAUNCHES